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REGULATING RESEARCH WITH VULNERABLE
POPULATIONS: LITIGATION GONE AWRY
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I. INTRODUCTION
Current litigation in New York, T.D. v. New York State Office of
Mental Health (OMH),' challenges OMH regulations governing re-
search with human subjects. The outcome of this litigation will ulti-
mately determine whether research in New York may be conducted
with children and with incapacitated adults, and under what circum-
stances. The repercussions may prevent numerous studies from going
forward and ultimately put a halt to research that may have provided
participants with access to effective treatment and significantly im-
proved the well-being of other individuals suffering from mental ill-
ness and other cognitive impairments.
The New York experience demonstrates the consequences of liti-
gation in which the central issues of a complex matter are inade-
quately examined. The result in this instance may be the
establishment of research rules which will have significant adverse im-
pacts on individuals with mental illness or other cognitive impair-
ments, their family members, and researchers in this and other fields.
The New York experience stands in stark contrast to the consensus
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building approach adopted by Maryland,2 both in its process and
likely outcome.
II. BACKGROUND
A. Histoiy of Research in Office of Mental Health Facilities
OMH has included research into the causes of severe and persis-
tent mental illness as one component of its mission for more than 100
years. In 1890, legislation was passed in New York State placing all
chronically mentally ill individuals under the protection and care of
the state.3 Several years later, additional legislation was passed creat-
ing the nation's first institute dedicated to psychiatric research. The
New York State Psychiatric Institute (NYPI) opened in 1896 and has
been continuously supported by the state until the present time. NYPI
was mandated to conduct research into the causes, prevention, and
treatment of mental illness.4 A second dedicated research facility, the
Nathan Kline Institute for Psychiatric Research, was opened by OMH
in 1952. Research studies are also conducted at many of the clinical
psychiatric hospitals operated by the state. As recognized by the Na-
tional Institute of Mental Health, "[t] he State of New York includes
some of the most distinguished research institutions in the United
States."5 Research carried out within OMH facilities is under the over-
all supervision of a Deputy Commissioner for Research. All research
is carried out subject to the approval of, and ongoing review and mon-
itoring of, a federally-approved institutional review board (IRB).6
Among the milestones accomplished by researchers in OMH were the
discovery of the infectious etiology of "general paresis of the insane,"
the first genetic studies of schizophrenia, the first clinical trials of
chlorpromazine (the first antipsychotic medication to become avail-
able in the United States), the first lithium clinic in the country (for
treatment of manic depressive illness), and, more recently, the discov-
ery of the genetic defect in Wilson's disease (a disease of copper me-
tabolism that can cause a type of psychosis).
2. SeeJack Schwartz, Office of Md. Att'y Gen., Third Report of the Attorney General's
Research Working Group (August 1997) (the Third Report is reprinted in Appendix B to
this issue of the Journal of Health Care Law & Policy).
3. See Act of April 15, 1890, ch. 126, 1890 N.Y. Laws 303.
4. See LAWRENCE C. KOLB & LEON ROIZIN, THE FiRTr PSYCHIATRIC INSTITUTE 7-8 (1993).
5. Letter from Rex William Cowdry, Acting Director, National Institute of Mental
Health, to Mr. John V. Tauriello, Deputy Commissioner of Mental Health and Counsel,
New York State Office of Mental Health (January 26, 1996).
6. See Protection of Human Subjects, 45 C.F.R. § 46.101 (1997).
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B. Research Regulations Prior to 1990
In 1975, the New York State Department of Mental Hygiene, of
which what is now OMH is one component agency, issued regulations
for research involving human subjects. 7 These brief regulations pro-
vided the following:
" Research participation could not come into substantial
conflict with the patient's individual service plan or de-
prive a patient of any right or privilege.8
" Informed written consent was required to be obtained
from patients.9 If a patient did not have sufficient capac-
ity, consent could be obtained from the facility director if
the IRB established that the project had overriding thera-
peutic importance for a condition presented by the pa-
tient and that the project could not be carried out
without the participation of such patients.'
* Use of experimental drugs or treatment procedures had
to be approved by the OMH Division of Research. 1
In the late 1980s, under the leadership of the Deputy Commis-
sioner for Research, the adequacy of these research regulations was
reviewed." Particular attention was given to the need to safeguard
the most vulnerable populations participating in research.' At this
time, a number of significant problems were identified.' 4 As an in-
terim measure, while revised regulations were being developed, OMH
issued a policy memorandum 15 which addressed some of the most
critical deficiencies by adding the following requirements:
* Researchers were required to obtain an assessment of ca-
pacity of all adult patients, both outpatients and inpa-
tients, and document the results in the individual's
medical record.'" For outpatient protocols which in-
volved no more than minimal risk and/or a non-vulnera-
ble subject population, the IRB was authorized to permit
7. See N.Y. COMP. CODES R. & REcs. tit. 14, § 27.10 (1997).
8. See id. § 27.10(a).
9. See iU § 27.10(b).
10. See id.
11. See id. § 27.10(c).
12. See Memorandum from Heinz Lehmann, Deputy Commissioner for Research, New
York State Office of Mental Health and Susan J. Delano, Clinical Research Coordinator,
Research Foundation for Mental Hygiene, Inc. to OMH Facility Directors and IRB
Chairpersons Uuly 31, 1987) (unpublished memorandum, on file with authors).
13. See id.
14. See id.
15. See id,
16. See id.
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the research team itself to make the capacity assess-
ment. 17 All other outpatient protocols were subject to
the capacity assessment procedures for inpatient proto-
cols."8 These procedures required that the capacity of in-
patients be assessed by at least two people, including an
investigator from the research team and a member of the
treatment team who was not affiliated with the research.' 9
Both were required to be licensed health care profession-
als, and one was required to be a psychiatrist or clinical
psychologist.20
" For patients found capable of consenting, and with the
patient's consent, family members, significant others, and
close friends who had been involved in treatment deci-
sions were to be informed about the patient's decision to
participate.2'
* Consent for an incapable patient's participation in re-
search was required to be obtained from both the facility
director and the patient's spouse, parent, adult child,
guardian, or court of competent jurisdiction. 22 Docu-
mentation of the patient's lack of objection to participa-
tion was required.23
* The researcher was required to honor the incapacitated
patient's objection to participation unless a court order
was obtained.24 It was assumed that a court would only
authorize research offering therapy not available outside
the research context where there was no acceptable alter-
native treatment and the research was consistent with the
treatment needs of the patient.2 5
C. Development of 1990 Regulations
As noted above, the 1975 regulations were inadequate, particu-
larly with regard to issues of capacity and-surrogate consent.26 Build-
ing on the interim guidelines, OMH undertook a revision of its
research regulations. Three major goals guided this process:
17. See id.
18. See id.
19. See id.
20. See id
21. See id at 2.
22. See id. at 3.
23. See id.
24. See id at 4.
25. Se id
26. See N.Y. COMP. CODES R. & REGS. tit. 14 § 27.10 (1997).
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1) maximization of patient autonomy and control by pa-
tients over their participation in research;
2) protection of the rights and welfare of these potentially
vulnerable populations; and
3) creation of an environment that makes it possible to
carry out important and needed research with these patient
groups.
27
In drafting the regulations, OMH attempted to achieve a princi-
pled and workable balance of these goals. Based upon clinical reality,
respect for patients and developments in the law, a consensus had de-
veloped among health professionals that psychiatric patients should
be presumed capable of consenting to research participation. 28 More-
over, status as an inpatient or outpatient was not to be considered
determinative of capacity.2 9 However, since some patients do lack ca-
pacity to consent, IRBs were charged with the responsibility of exam-
ining the proposed research and the subject population to tailor
capacity assessment procedures to the specific research protocol.
3 0
When an IRB had reason to believe that patients might lack sufficient
capacity to give informed consent, the IRB was authorized to require
that capacity assessments be conducted by someone not affiliated with
the research and to set specific qualifications for the person(s) who
assessed capacity.31
The regulations also provided that a member of the participant's
treatment team was required to approve all research that involved
more than minimal risk.32 The care and treatment of hospitalized pa-
tients is under the direction of a multi-disciplinary treatment team,
usually consisting of a psychiatrist, social worker, nurse, activities ther-
apist, and often a psychologist.33 This treatment arrangement is stan-
dard for all inpatients, including those participating in research
protocols.
In addition, the regulations stated that all patients, regardless of
capacity, could, at any time prior to or during participation in re-
27. See Susan J. Delano & Jay L. Zucker, Protecting Mental Health Research Subjects Without
Prohibiting Progress, 45 HosP. & COMMUNITY PSYCHIATRY 601-03 (1994).
28. See Rivers v. Katz, 495 N.E.2d 337, 342-43 (N.Y. 1986).
29. See N.Y. COMP. CODES R. & REcs. tit. 14 § 527.10.
30. See id. § 527.10(e) (2) (ii).
31. See id.
32. See id. § 527.10(d)(3). "Minimal risk" is defined to mean that "the risks of harm
anticipated in the proposed research are not greater... than those ordinarily encountered
in daily life or during the performance of routine physical or psychological examinations
or tests." § 527.10(d)(5) .
33. See Paul Rodenhauser, Psychiatrists as Treatment Team Leaders: Pitfalls and Rewards, 67
PSYCHiATRIC Q. 11 (1996).
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search, object and be withdrawn from participation. 34 For incapable
participants, the objection of any of the members of the classes of
authorized surrogates was equally effective.35 Any such objection was
determinative except that, if the research provided a prospect of di-
rect benefit available only in the context of the research, participation
in such research could occur if approved by a court.3 6 Moreover, the
IRB was required to determine, for research involving incapable sub-
jects, that the research could not be done without such subject's inclu-
sion and that the research was likely to produce knowledge of
overriding therapeutic importance for a condition presented by the
patients in question.
37
Finally, preference was to be given to surrogates chosen by the
patient. 3 In the absence of a patient-chosen surrogate, consent could
be obtained from a patient's spouse, parent, adult child, adult sibling,
or guardian.3 9 If no surrogates in the other categories were available,
consent could be obtained from a court or, in special cases, (e.g., per-
sons in non-traditional relationships) consent could be provided by a
carefully defined "close friend."4° This identification of potential
surrogate decision-makers reflected the provisions found in the New
York state statute enacted in 1987 concerning "Do Not Resuscitate"
orders.4'
Two additional factors regarding the OMH regulations are rele-
vant to this discussion. The first is that the OMH regulations supple-
mented the federal regulations which govern how human subjects
research is conducted in this country.4" The OMH regulations did
not establish or change any principles or categories with regard to
likelihood of therapeutic benefit of the proposed research, degrees of
risk or funding source.
The second factor was that the process of developing the regula-
tions included extensive consultation with patient advocates, clini-
cians, researchers, state agency personnel - particularly the
Department of Health and members of IRBs. Thereafter, as required
34. See§ 527.10(e)(2) (vi), (vii).
35. See § 527.10(e) (2) (viii).
36. See § 527.10(e)(2)(vi-viii).
37. See § 527.10(d) (6).
38. See § 527.10(e)(2)(iii), (iv).
39. See § 527.10(e) (2) (iv).
40. 1&
41. N.Y. Pua. HEALTH LAw §§ 2960-72 (McKinney, 1997).
42. See Protection of Human Subjects, 45 C.F.R. § 46 (1997) (now referred to as the
Common Rule); Protection of Human Subjects, 21 C.F.R. § 50 (1997); Institutional Review
Boards, 21 C.F.R. § 56 (1997).
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by state law, 4" draft regulations were published in the State Register
for comment. 4 The proposed regulations were also distributed to
state agencies, facilities licensed and operated by the OMH, local gov-
ernment units, the Mental Health Services Council (an advisory
group, to the OMH Commissioner), consumer groups, and advocacy
groups. A number of groups provided comments. 45 These comments
questioned many aspects of the proposed regulations, including their
applicability, definitions, and issues related to surrogate consent. Fol-
lowing are summaries of the comments that are relevant to the issues
raised in the litigation:
4 6
* Six comments stated that research involving incapable
subjects should only be permitted when it involves a ben-
efit to the subject. OMH responded that while benefit to
an individual patient is highly desirable, research into
many currently irreversible conditions such as Hunting-
ton's Disease and Alzheimer's Disease cannot benefit the
subjects of the research.47 To prohibit research when
there is no direct benefit to the patient would mean the
end to research into many serious illnesses. To clarify
that the IRB is required to conduct a risk/benefit analy-
sis, the proposed regulations were revised to give greater
emphasis to the sections of the federal regulations relat-
ing to evaluation of risks and benefits, and the minimiza-
tion of risks.4"
" One comment suggested that when a person's capacity is
questionable and the research involves more than mini-
mal risk, an independent qualified consultant should de-
termine capacity.49 OMH responded that the proposed
regulations required the IRB to evaluate the nature of the
research and the subject population to determine when
43. See N.Y. A.P.A. LAw §§ 201-02 (McKinney, 1997).
44. See Mental Illness Research, N.Y. St. Reg., May 23, 1990, at 23-24 (codified at N.Y.
COMP. CODES R. & REGs. tit. 14, § 527.10 (1997)).
45. Twenty one comments were timely received. These were submitted by mental
health professionals and providers such as state and county Mental Health Associations,
and operators of licensed psychiatric inpatient units; by advocacy groups such as Project
Release, Mental Health Recipient Empowerment Project, and the Commission on Quality
of Care for the Mentally Disabled; and by individuals. In addition, a submission by Disabil-
ity Advocates, Inc. which was received subsequent to the time period for comments estab-
lished by the New York State Administrative Procedure Act was also considered.
46. See generally Mental Illness Research, N.Y. St. Reg. August 29, 1990, at 27-31 (1997)
[hereinafter Mental Illness Research].
47. See id. at 30.
48. See id.; see also Protection of Human Subjects, 45 C.F.R. § 46.111 (1997).
49. See Mental Illness Research, supra note 46, at 30.
[VOL. 1:154
RESEARCH WI-H VuLNERABLE POPULATIONS
an independent assessment of capacity is required."0
This complex decision is best left to the judgment of the
IRB.
" Two comments stated that the decision in Rivers v. Katz"l
requires that capacity assessments/determinations must
be made by a court.5 2 This is not OMH's interpretation
of the Rivers opinion."3 Such a requirement would mean
that all patients would be presumed incapable of con-
senting until a judicial determination of capacity is
made.54 This stigmatizing practice would be detrimental
to OMH's ability to provide treatment and would impose
a tremendous and unwarranted barrier to the conduct of
research.5
" Two comments stated that it should be conclusively as-
sumed that all patients have sufficient capacity to con-
sent.56 OMH disagreed believing that some patients
would lack capacity, and thus, safeguards are required to
ensure that the interests of those patients who lack capac-
ity are protected.57 The IRB must determine who shall
assess capacity, and the person obtaining consent must
sign the consent form to attest to the person's capacity.58
" Eleven comments challenged surrogate consent.59 OMH
responded that the surrogates named in the regulations,
particularly those chosen by the patient, can more appro-
priately articulate the patients' wishes and interests than
can judges. 60
" Four additional comments challenged the authority of a
"close friend" to consent on behalf of an incapable sub-
ject.6" OMH responded that "close friend" was incorpo-
rated in recognition of the large number of people in
non-traditional relationships and the large number of
people whose primary care giver is not a family mem-
50. See id.
51. 495 N.E.2d 337 (N.Y. 1986).
52. See Mental Illness Research, supra note 46, at 30.
53. See id.
54. See id.
55. See id.
56. See id.
57. See id.
58. See id.
59. See id. at 30-31.
60. See id. at 31.
61. Id.
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ber.6" As noted above, this principle had already been
recognized in New York law."3
* Nine comments asked for specification of the conditions
under which an application could be made for a court
order to override a patient's objection.64 This suggestion
was adopted.
" One comment objected to any provision allowing an inca-
pable subject's objection to be overridden.6 5 OMH re-
sponded that the override provision is intended for
situations in which there is no standard treatment for a
condition or the patient is refractory or intolerant of stan-
dard therapy.' This would allow treatment over objec-
tion with an experimental drug, but only when
specifically authorized by a court.
Based upon the public comment, the proposed regulations were
revised. The revised proposed regulations were distributed, the seven
responses received, again presenting divergent perspectives, and all
responses were considered prior to final adoption.67
D. Experience with 1990 Regulations
It appears that researchers and IRBs made the transition from the
minimal 1975 regulations to the 1990 regulations in a workable man-
ner. The regulations were in effect for approximately five years, and
other than the litigation, we are aware of no complaints about the
regulations or their implementation. It should be noted that many
avenues for complaints were available including the Commission on
Quality of Care for the Mentally Disabled, an independent state over-
sight body. Moreover, as required by the federal research regula-
tions, 68 all research consent forms include the name and telephone
number of a person that participants (or surrogates) may contact if
they have any questions about their rights.6" Typically this person is
the IRB chairperson. In addition, individuals and organizations rou-
tinely contact the Commissioner of OMH with questions and con-
cerns, but no complaints regarding the research regulations were
62. See id.
63. N.Y. PuB. HEALTH LAW §§ 2960-72 (McKinney, 1997).
64. See Mental Illness Research, supra note 46, at 30.
65. See id.
66. See id.
67. These comments were submitted by Disability Advocates, Inc., New York Lawyers
for the Public Interest, Inc., the Free Association for Rights and Representation, Inc., two
individuals and two representatives of research institutions.
68. See Protection of Human Subjects, 45 C.F.R. § 46.116(7) (1997).
69. See id.
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received to our knowledge. Finally, the regulations were described in
a widely read peer-reviewed publication,7" and the Federal Office for
Protection from Research Risks has noted its appreciation of "the
commitment of the New York State Department of Mental Health to
the protection of human subjects."7"
III. SETTING RESEARCH POLICY. THROUGH LITIGATION
A. Summary of Plaintif[s Claims
While the 1990 regulations were considerably more protective of
research participants than the previous regulations; they were substan-
tially flawed in the opinions of some groups. In 1991, three legal ad-
vocacy groups - Disability Advocates, New York Lawyers for the Public
Interest, and The Mental Hygiene Legal Service, on behalf of six pa-
tients hospitalized at various New York State Psychiatric Centers
brought the T.D. case against OMH and the State Department of
Health.72 None of the six patients claimed to have been a participant
in a research project. However, they alleged that they were "fearful"
of being included in research against their will. 73 These patients had
received standard medications administered over their objections, 7 in
accordance with a 1986'ruling of New York's highest court permitting
such treatment upon ajudicial determination that the patient-was in-
capable of making treatment decisions and that the proposed treat-
ment was appropriate.75
The TD. suit concerned both OMH operated facilities as well as
OMH licensed facilities (i.e., psychiatric units in general hospitals and
in teaching hospitals affiliated with academic departments of psychia-
try) in New York and was limited to more than minimal risk research
with minors and with adults who lack capacity to consent.76 The plain-
tiffs asserted a legal claim with two main elements:
70. See generally Delano & Zucker, supra note 27.
71. Letter from J. Thomas Puglisi, Director, Division of Human Subject Protections,
National Institutes of Health, to Susan Delano, Clinical Research Coordinator, Research
Foundation for Mental Hygiene, Inc. (December 2, 1996) (unpublished letter on file with
authors).
72. T.D. v. New York State Office of Mental Health, 626 N.Y.S.2d 1015 (N.Y. Sup. Ct.
1995), affd 650 N.Y.S.2d 173 (App. Div. 1996), appeal dismissed &y 680 N.E.2d 617 (N.Y.
1997), leave to appeal granted by 684 N.E.2d 281 (N.Y. 1997), and appeal dismissed by 1997 WL
785461 (N.Y. Dec. 22, 1997).
73. T.D., 650 N.Y.S.2d at 177.
74. See id.
75. See Rivers v. Katz, 495 N.E.2d 337, 343 (1986).
76. T.D., 626 N.Y.S.2d at 1017.
1998]
JOURNAL OF HEALTH CARE LAW & POLICY
. 1) that OMH lacked the authority to. promulgate regulations re-
garding research on human subjects because state law granted such
authority to the Department of Health;" and
2) that the specific regulations governing the procedures for the
"non-consensual participation by mentl: patients in potentially high
risk [non-therapeutic] experiments" s violated constitutional rights to
privacy and due process by permitting, inter alia, research consent
from a relative or "close friend" without a judicial determination of
incapacity and formal designation of a surrogate.79
The parties filed cross motions for summary judgment on these
legal claims in 1992.80 Plaintiffs alleged that risk and harm were asso-
ciated with research participation, but as the motions addressed only
questions of law, these allegations were never proven nor rebutted.'
Moreover, neither the actual risks and benefits of research participa-
tion nor the concepts and mandates of the federal regulations and
state law governing the conduct of research was ever meaningfully ex-
plored in this litigation.
In 1995, the court granted the Plaintiffs' Motion for Summary
Judgment, stating clearly that it was not ruling on the constitutional
claims but only on the question of OMH's statutory authority to issue
regulations concerning research."2 The court further limited the
scope of its ruling to non-federally funded research studies.8"
Defendants appealed the trial court's statutory ruling, and the
plaintiffs appealed that court's failure to rule on the constitutional
issues.8 4 In 1996, the intermediate appeals court, the First Appellate
Department of the New York State Supreme Court, issued its decision
on the cross appeals of the trial court's ruling on the cross motions for
summary judgment."5 The appellate court concurred with the lower
77. See id. at 1021.
78. Id. at 1017.
79. See id.
80. See id. at 1018.
81. Plaintiffs motion for summaryjudgment was supported by affidavits which claimed
research participants were exposed to extreme risk and suffered terrible harms. In support
of these claims, plaintiffs attached over 2,500 pages of excerpts from investigative resports,
consent forms, the Physicians Desk Reference, etc. Defendants contended that, when read
in their entirety, the reports, forms and PDR demonstrated the inaccuracy of the conclu-
sions drawn by the plaintiffs.
82. See T.D., 626 N.Y.S.2d at 1022-23.
83. See id. at 1023-24.
84. See T.D., 650 N.Y.S.2d 173.
85. See id.
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court that OMH lacked the statutory authority to issue the regulations,
and also ruled on the constitutional questions. 6
Many aspects of the court's constitutional analysis and conclu-
sions are confusing, but the essence of the ruling was that the OMH
regulations violated the right to due process in that they did not spec-
ify uniform qualifications and protocols for the independent evalua-
tion of research participants' mental capacity, did not provide for
notice of that evaluation to the person or a means to object to the
determination, permitted a relative to give surrogate consent without
a judicial proceeding, and thus permitted non-therapeutic research
which posed "more than minimal risk" to research subjects without
their consent or the consent of a suitable surrogate." Like the lower
court, the decision clearly states that it applies only to non-federally
funded and non-therapeutic research."8 The court held that individu-
als who lack decision-making capacity may not participate in such re-
search if that research poses more than minimum risk to the research
subject unless the research subject has previously given valid "specific
consent" or a suitable surrogate chosen by the subject has given con-
sent.8 9 Although the plaintiffs obtained two court decisions invalidat-
ing the regulations, they returned to the appellate division requesting
that it clarify its decision and broaden the scope to apply to federally-
funded studies and to therapeutic studies with the populations in
question.9" OMH also asked the court to clarify its decision, but both
motions were denied. 9'
Plaintiffs then appealed to New York's Court of Appeals, the
state's highest tribunal, again seeking to broaden the scope of the rul-
ing to apply to federally-funded and to therapeutic research involving
incapable adults and minors.92
B. Reallocating Agency Jurisdiction
The plaintiffs have contended, and the courts have thus far
agreed, that the New York State Department of Health (DOH) has
sole legal authority to issue regulations concerning human subject re-
search.9" It is true that DOH has authority in this area under New
86. See id. at 184-94.
87. Id.
88. See id at 184, 192.
89. Id. at 177.
90. See Plaintiffs'-Appellants' Notice of Motion for Leave to Appeal at 23-35, 650
N.Y.S.2d 173.
91. See T.D., 650 N.Y.S.2d at 176.
92. See id (at the time of the original writing of this article, the appeal was pending).
93. See i&
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York State Public Health Law;94 yet the court ignored important facts.
It had been a longstanding understanding between DOH and OMH
that OMH had the authority to issue regulations which provided spe-
cific requirements for psychiatric research. In fact, DOH had not
promulgated regulations regarding human subjects research, but had
participated in the development of, and had recognized, the OMH
regulations and system for monitoring psychiatric research. This reli-
ance upon OMH expertise in exercising administrative responsibility
continues, for example, with OMH licensing the psychiatric units in
general hospitals whose overall licensure is statutorily committed to
DOH. Thus the court's invalidation of the OMH regulations upset in-
teragency coordination that had worked well for years, and did so for
reasons having nothing to do with the substance of the research
regulations.
C. Misperception of Risks and Benefits
As noted above, none of the plaintiffs in the law suit had suffered
any tangible harms as a result of participation in research, since, in
fact, none of them had participated in research. Rather, the suit was
based on their fears that they might be included in a research proto-
col without their informed consent.95 Because there was no real harm
suffered, the claims were based upon hypothetical harms. Unlike
cases where actual injury is suffered and the lawyers for the plaintiffs
must litigate based upon evidence of harm,. in this case the lawyers
were free to assert possible harms untethered to facts. The structure
of the litigation thus lent itself to rhetoric. Moreover, because the
trial court ruled on motions for summary judgment and no real fac-
tual record was developed, the appellate review of the issues reflected
the emotions associated with risk and vulnerability rather than the re-
ality of research.
The plaintiffs contended that high-risk research was being carried
out with minors and incapable adults, and that this high-risk research
offered absolutely no benefit to the participants" and was akin to Naziatrocities.97 In the papers filed with the court of appeals, plaintiffs
94. See N.Y. PuB. HEALrH LAw § 2446 (McKinney, 1997).
95. See TD. 626 N.Y.S.2d 1015.
96. See Plaintiffs' Complaint at para. 21, 28, T.D. v. New York State Office of Mental
Health, 626 N.Y.S.2d 1015 (N.Y. Sup. Ct. 1995) (No. 5136/91); Plaintiffs'-Appellants' State-
ment in Support of Motion for Leave to Appeal at 4, T.D. v. New York State Office of
Mental Health and New York Department of Health, 650 N.Y.S.2d 173 (App Div. 1996)
(No. 5136/91) [hereinafter Plaintiffs'-Appellants' Motion for Leave to Appeal].
97. See Patricia Cohen, Patients at Risk: Experiments in Mental Hospitals, NEw YORK NEws-
DAY, Feb. 3, 1993, at 3. "'We may not have the horror stories in numbers, but the possibility
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made the following statement: "This appeal raises. novel issues which
are of paramount importance to patients in psychiatric facilities who
cannot defend themselves from non-consensual experiments which
present a significant risk of harm and death and which may not even
offer an iota of benefit."9 Plaintiffs proceeded to repeatedly refer to
"risky," "wholly non-therapeutic" experiments. 9
The plaintiffs' paper's also stated,
iT]he OMH experiments involve both "FDA approved and
non-FDA-approved experimental antipsychotic and psycho-
tropic drugs" and "highly invasive painful testing proce-
dures" such as spinal taps, inhalation of radioactive gas,
attachment to intravenous lines for several hours, radiation
exposure, and skin biopsies .... The experiments are "capa-
ble of causing permanent harmful or even fatal side
effects."'00
Contrary to these assertions, to the best of our knowledge, in fa-
cilities operated or licensed by OMH, no studies are done that do not
involve patient assent,'01 no non-therapeutic elements of any studies
involve more than a minor increase over minimal risk, and there are
no more than a minor increase over minimal risk studies that are
"wholly non-therapeutic." The categorization of risk in human sub-
jects research presents a number of complicated issues. However,
utilizing generally accepted definitions, 0 2 no high-risk research is be-
ing carried out, to our knowledge, in OMH operated or licensed facili-
ties. In addition, the procedures the plaintiffs refer to are all
performed in the course of ordinary medical care in hospitals all over
the country. They are not highly invasive, they are either not painful
or are only minimally so, and the drug side effects referred to are
those listed in the Physicians'Desk Reference as potential side effects of
FDA-approved medications routinely prescribed in standard psychiat-
ric treatment.
of what happened in Nazi prison camps or Tuskegee exists' said Ruth Lowenkron, an attor-
ney with New York Lawyers for the Public Interest who argued the case in State Supreme
Court in Manhattan." Id. at 3.
98. Plaintiffs'-Appellants' Motion for Leave to Appeal, supra note 96, at 20.
99. Id.
100. Id.
101. Though the regulations contemplated the possibility that court authorization for
treatment over objection could be sought to provide necessary treatment not otherwise
available, we are not aware of any case in which such authorization has been sought.
102. See Evan G. De Renzo, Decisionaily Impaired Persons in Research: Refining the Proposed
Refinements, 25J.L. MED. & ETHICS (1997).
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D. Shrinking the Category of Therapeutic Research
While the litigation was proceeding, numerous attempts were
made to settle the matter through face-to-face dialogue between the
parties. One issue that was particularly contentious was how to char-
acterize research that was expected to benefit participants and con-
tained a non-therapeutic element. Plaintiffs insisted on rigidly
categorizing every research protocol as either therapeutic or non-ther-
apeutic. They defined any protocol, in its entirety, as non-therapeutic
if any element of the protocol was non-therapeutic, thus significantly
shrinking the category of research considered therapeutic.'
The consequences of this categorization are very significant. For
example, protocols involving non-therapeutic uses of procedures such
as Positron Emission Tomography (PET) scans, no matter how much
potential benefit they otherwise offer, are classified as non-therapeutic
because of such categorization. Although plaintiffs' basis for classify-
ing research was never examined by the courts, the appellate divi-
sion's decision effectively adopted their classification and banned all
non-therapeutic, more than minimal risk research involving minors or
incapable adults, unless such. research is federally-funded."0 4
In New York, IRBs have traditionally been responsible for evaluat-
ing risk/benefit ratios of protocols, to assure that even if a protocol
contains non-therapeutic elements, the overall benefits of the proto-
col outweigh the risk of the non-therapeutic elements in question. 0 5
Guidance was provided to the IRBs by the OMH regulations, which,
for emphasis, repeated the federal requirements for approval of re-
search."0 6 The OMH regulations also provided that treatment teams
must approve more than minimal risk research 0 7 and stipulated that
incapable adults could only participate in research if it could not be
done without their participation and only if the knowledge likely to be
produced had overriding therapeutic importance for the understand-
103. At one point in the litigation, before the appellate division decision, the defend-
ants agreed to a stipulation reflecting this categorization in exchange for an amendment of
the definition of "therapeutic." Stipulation of Feb. 9, 1996, 626 N.Y.S.2d 1015 (Sup. CL
1995) (Index No. 5136/91). This definition had included the language "and is only avail-
able in the context of research," which would have allowed only research involving investi-
gational drugs and would have banned all research involving marketed drugs thus
adversely impacting research seeking to establish lower dosage levels of medications. 1d.
104. See T.D. v. New York State Office of Mental Health, 650 N.Y.S.2d 173 (App. Div.
1996), appeal dismissed, 680 N.E.2d 617 (N.Y. 1997), leave to appeal granted by 684 N.E.2d 281
(N.Y. 1997), and appeal dismissed by 1997 WL 785461 (N.Y. Dec. 22, 1997).
105. See N.Y. COMP. CODs R. & REas. tit. 14, § 527.10'(1997).
106. See id. § 527.10(d).
107. See id. § 527.10(d)(3).
[VOL. 1:154
RESEARCH WITH VULNERABLE POPULATIONS
ing or treatment of a condition presented by the patient in
question.?10
Although we disagree with the plaintiffs' categorization of proce-
dures like lumbar punctures or PET scans as "highly risky," it is true
that these procedures might be viewed by some as acceptable if neces-
sary diagnostic or therapeutic components of treatment, but not ac-
ceptable as non-therapeutic components of a research protocol, even
if the protocol is otherwise therapeutic. However, the small degree of
risk or discomfort caused by the non-therapeutic procedure is mini-
mal in contrast to the substantial morbidity or mortality of the condi-
tion being studied (e.g., schizophrenia, suicidal depression) and the
anticipated benefit to the subject from the therapeutic aspects of the
protocol that may be largely or entirely unavailable outside of the con-
text of research.
Absent specific evidence of adverse consequences from the non-
therapeutic use of common diagnostic procedures, absolutely ban-
ning their use unnecessarily impedes the development of better treat-
ments, which is particularly unjustified given the overall benefits to
research participants. If problems were to be identified regarding
such use, tailored standards or mechanisms should be explored
before an absolute legal ban is considered.
E. Combining Rigid Categories and Risk Exaggeration
Another fundamental difference between the plaintiffs and OMH
concerned the use of the concept of a "minor increase over minimal
risk."1" 9 Although this level of risk classification was proposed by the
National Commission for the Protection of Human Subjects of Bi-
omedical and Behavioral Research 1 ° and adopted in the federal regu-
lations regarding research involving children,"1 the plaintiffs would
not accept the concept. As a result, research posing only a minor in-
crease over minimal risk was categorized along with highly risky re-
search as simply "more than minimal risk" and thus banned under the
court's ruling.
"Minimal risk" is defined in the federal research regulations to
the effect that "the probability and magnitude of harm or discomfort
anticipated .in the research are not greater in and of themselves than
108. See id § 527.10(d)(6).
109. THE NATIONAL COMMISSION FOR THE PROTECTION OF HUMAN SUBJECTS OF BIOMEDI-
CAL AND BEHAVIORAL RESEARCH, REPORT AND RECOMMENDATIONS: RESEARCH INVOLVING
CHILDREN, DHEW Pub. No. (OS) 77-0004 at 8 (1997).
110. See id at 7-9.
111. Protection of Human Subjects, 45 C.F.R. § 46.406(a) (1997).
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those ordinarily encountered in daily life or during the performance
of routine physical or psychological examinations or tests.""' 2 The
provisions in the federal research regulations concerning children
permit research which is not expected to benefit the child and in-
volves risk that is only a "minor increase over minimal risk" if certain
conditions are met." 3 Although this risk level is not further defined
by the regulations, its application to research involving minors in-
cludes an instruction to IRBs to evaluate the experiences ordinarily
encountered by the subjects, including their experiences during the
course of regular treatment, in making its determination about the
risk posed by a research intervention to a particular subject
population. 1 4
Examples of elements in OMH protocols determined by IRBs to
be non-therapeutic and more than minimal risk, which plaintiffs re-
peatedly referred to as "highly risky," are PET scans and lumbar punc-
tures. We would argue that these procedures should be categorized as
no more than a minor increase over minimal risk, an argument others
make as well:
There are those who argue that... [LPS and PET scans]
are, if not minimal risk, not more than a minor increase
above minimal risk. Although LPS and PETs are not on the
list of minimal-risk procedures contained in the U.S. re-
search ethics regulations, Title 45, Code of Federal Regula-
tions, Part 46 (45 C.F.R. 46), this list has not been updated in
many years and these procedures may eventually be
added." 5
In fact, in New York, no more than minimal risk non-therapeutic
research elements are carried out that we know of with the popula-
tions in question where the non-therapeutic elements present more
than a minor increase over minimal risk to participants.
In its now invalidated research regulations, 1 6 OMH had at-
tempted to supplement federal regulations and provide overall gui-
dance to IRBs as they carefully weighed the risks and benefits of
research protocols. OMH's goals were to require reasonable protec-
tion for patients while acknowledging their autonomy, yet at the same
time to avoid setting barriers so high that they could block scientific
112. !d. § 46.102(i).
113. Id. § 46.406(a).
114. See id. § 46.406(b).
115. Evan G. DeRenzo, Surrogate Decision Making for Severely Cognitively Impaired Research
Subjects: The Continuing Debate, 3 CAMBRIDGE Q. HEALrHCARE ETHics 539, 540 (1994).
116. See N.Y. COMp. Coos R. & REGS. tit. 14, § 527.10 (1997).
(VOL. 1:154
RESEARCH WITH VULNERABLE POPULATIONS
progress -progress, to .benefit the very patients being protected. The
plaintiffs' argument that, research with children or..incapable adults
could be continued by simply deleting any non-therapeutic more than
minimal risk elements disregards. the realities of scientific research.
Some vitally important questions can only be addressed by employing
procedures that are not entirely risk-free but provide answers that
could lead to important therapeutic benefits. Risk is encountered
daily in routine health care, in the form of diagnostic evaluations to
"investigate" the etiology of clinical symptoms. For example, proce-
dures such as PET scans, angiograms, laparoscopies, or even "explora-
tory" laparotomies are carried out to search for the disease source,
with no guarantee that positive findings will result. In our view, small
increments of risk are at times necessary in the context of carefully
conducted clinical research in order to find ways to relieve the ex-
treme pain and suffering of severe mental illness.
IV. IMPACr OF NEW YORK LITIGATION
Unless corrected by the New York State Court of Appeals, the de-
cision as now written by the New York courts will mean that some sig-
nificant research that is currently being conducted on mental illness
will not be able to continue, as. illustrated in the following two
examples:
1. A major academic department of psychiatry has a large portfo-
lio of foundation-funded research." 7 Researchers at this institution
recently described their plan to begin a sensitively and carefully
designed PET brain-imaging study of autistic children."' Childhood
autism is a pervasively disabling, severe condition. New findings are
crucial to better understand this condition, and taking advantage of
new non-invasive brain-imaging technologies makes eminent sense.
The researchers had to be informed that because this study was non-
therapeutic, it was now illegal in New York.
2. At NYPI, a study is being carried out of suicidal adolescents.
Suicide is the second leading cause of death among adolescents age
15-19, and it has increased by over 300% since 1950 in this age
group." 9 Studies in adults have revealed low central nervous system
117. Personal communication between David Silbersweig, M.D., Cornell Medical Col-
lege, and John Oldham, M.D., Director, New York Psychiatric Institute (March 26, 1997).
118. See id.
119. See Alan L. Berman & David A. Jobes, Suicide Prevention in Adolescents (Age 12-18), 25
SUICIDE & LIFE THREATENING BEHAVIOR 143 (1995).
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serotonin levels in certain patients at highest risk for suicide. 120 Other
studies, however, have established that one cannot automatically apply
findings that hold in adults to younger populations.' 2' The study in
question involves hospitalizing highly suicidal youngsters at NYPI, and
providing at no cost to them, several months of enormously therapeu-
tic intensive inpatient treatment. 2 2 These minors assented to partici-
pate in the research, and their parents gave informed consent.22 A
crucial component of this study is the performance of a lumbar punc-
ture, or spinal tap, a diagnostic procedure, of which the main risk is
that, in about ten to fifteen percent of cases, it causes a bad headache,
which usually subsides within twenty-four hours.' 24 It is a test that is
carried out every day in every general hospital. Because this more
than minimal risk procedure is non-therapeutic, the entire study is
categorized as non-therapeutic and was suspended due to this litiga-
tion. Only because federally-funded studies were exempted and this
study is part of the research program in a National Institute of Mental
Health-funded Child Center grant, could this study be resumed. If
the plaintiffs were successful in their attempt in the court of appeals to
halt such federally-funded studies as well, this research project would
have been prohibited. It is clear from plaintiffs' letter to the New York
Times,125 that they expected the T.D. litigation to impact all medical
research. Thus, for example, if a child developed leukemia and the
parents of the child wished to enroll their child in a treatment re-
search protocol involving a promising new medication not yet other-
wise available, the parents would be unable to do so if the study
120. See Peter Nordstrom et al., CSF 5-HIAA Predicts Suicide Risk After Attempted Suicide, 24
SUICIDE & LIFE-THREATENING BEHAVIOR 1, 2 (1994).
121. See Benedetto Vitiello & Peter S. Jensen, Medication Development and Testing in Chil-
dren and Adolescents: Current Problems, Future Directions, 54 ARCHIVES GEN. PSYCHIATRY, 871-76
(1997).
122. See Biological Studies in Suicidal Adolescent Inpatients, Fed. Grant No.3 Rol MH
47113-0451 (unpublished protocol on file with co-authorJohn Oldham, M.D.) This multi-
site treatment study sought to study the effects of some antidepressant medications on
children diagnosed with depression, suicidal tendencies, or anxiety. See id. at 113. The
NYPI inpatient research ward supplied "all supportive inpatient services, including psycho-
logical assessment, close nursing care, and careful medical supervision." Id.
123. See id. at 113. "Both parent and adolescent are provided with their own consent
forms, and both must sign before the study begins." Id. There are "two safeguards" estab-
lished by this protocol: 1) both must sign the consent form, and 2) "the adolescent has at
least a week between the time of signing consent and the beginning of the biological tests
to change his or her mind." Id.
124. See ROBERT A. FISHMAN, CEREBROSPINAL FLUID DIsEASE OF THE NERVOUS SYSTEM 172
(2d ed. 1992).
125. Letter from Cliff Zucker et al., to Editor, N.Y. TIMES, January 7, 1997, at A16.
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included a non-therapeutic element such as a bone scan. Such a study
would be illegal in New York State.
Throughout the litigation, the defendants attempted to impress
upon plaintiffs the adverse impact on research that would occur if
they prevailed. At one point we presented them with a hypothetical
example" 6 in the hopes that they would at least recognize the prob-
lematic consequences of the rules they sought to establish, The hypo-
thetical situation involved a medication X, a new anti-psychotic agent
that is thought to be very effective if treatment commenced immedi-
ately following acute onset of the illness. The research would include
individuals in their early twenties, thus unlikely to have executed ad-
vance directives, suffering from levels of disability that would likely
render them incapable of giving informed consent. The relative
safety of X has been established in FDA-regulated Phase I/I1 trials,
and an IRB is considering a Phase III pilot protocol to study the de-
gree of efficacy. A brain scan or lumbar puncture is needed to under-
stand X's locus of action in the brain and its metabolic impact on the
patient's health and on the disease processes, in order, ultimately, to
develop the next generation of safer, more effective medication. Such
procedures were necessary to complete the development of medica-
tion X and to obtain its FDA approval. The rules which plaintiffs seek
to establish would absolutely prohibit this research." 7
V. CONCLUSION
Research must be done in a careful, thoughtful, and heavily re-
viewed and scrutinized way. It must be done ethically and respect-
fully, attending to patients' rights. These critical concerns, however,
must be integrated with the need to make available promising treat-
ments for devastating illnesses as well as the need to continue the de-
velopment of better treatments, which can only be discovered through
research. A plan like the Maryland proposal accomplishes such a de-
sirable balance. Unfortunately, the results to date of the court process
in New York do not, in our opinion, achieve this goal.
126. Letter from Stephan Haimowitz to Cliff Zucker, attorney representative for plain-
tiffs, also working with public service law office serving persons with mental and physical
disabilities and Ruth Lowenkron (November 1, 1995) (copy on file with co-author Stephan
Haimowitz, J.D.).
127. When presented with this scenario, plaintiffs responded that the problem would
rarely arise because such studies could probably be done with patients who were capable or
had executed advance directives, but if not, the research should be banned, regardless of
the consequences. Telephone conversation between Stephan Haimowitz, Cliff Zucker and
Ruth Lowenkron (November 21, 1995).
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